Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047
Authors:
- Alexandra M. LevineALAlexandra M. Levine
- Ariela NoyANAriela Noy
- Jeannette Y. LeeJLJeannette Y. Lee
- Wayne TamWTWayne Tam
- Juan Carlos RamosJRJuan Carlos Ramos
- David H. HenryDHDavid H. Henry
- Samir ParekhSPSamir Parekh
- Erin G. ReidERErin G. Reid
- Ronald MitsuyasuRMRonald Mitsuyasu
- Timothy CooleyTCTimothy Cooley
- Bruce J. DezubeBDBruce J. Dezube
- Lee RatnerLRLee Ratner
- 1 January 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (1) , 58-64
Abstract
Purpose: Infusional chemotherapy is efficacious in patients with AIDS-related lymphoma, but it may be difficult to administer. We studied standard agents with rituximab plus pegylated liposomal doxorubicin (DR-COP) in an attempt to provide a more practical approach to therapy while ascertaining rates of response, potential infectious complications, and prognostic role of biologic markers. Patients and Methods: We conducted a prospective, multi-institutional phase II trial, employing (day 1) pegylated liposomal doxorubicin 40 mg/m2, rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 (not > 2 mg), and prednisone 100 mg orally on days 1 through 5, with concomitant antiretroviral therapy. Results: In 40 evaluable patients, median CD4 cells was 114/μL (range, 5 to 1,026/μL), and median HIV-1 viral load (VL) was 25,000 copies/mL. High or intermediate/high age-adjusted International Prognostic Index was present in 28%. Overall response was 67.5%, with complete remission in 47.5% (95% CI, 31.5 to 63.9). Of 19 complete responders, 84% had extranodal disease, 47% had CD4 < 100/μL, and 47% had VL > 50,000 copies/mL; one relapsed. With 25.5-month median follow-up, 62% (95% CI, 44 to 75) of patients remain alive. Sixteen patients (40%) experienced 22 infections, with grade 4 in only two (5%). No patient died as a result of infection during treatment; one had opportunistic infection. Conclusion: Profound immunodeficiency and high HIV-1 viral load do not preclude attainment of complete response after DR-COP with highly active antiretroviral therapy. The regimen is tolerable, and use of rituximab was not associated with death as a result of infection during treatment. This approach may be useful in patients in whom the more intensive infusional regimens are impractical.Keywords
This publication has 38 references indexed in Scilit:
- Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyLeukemia, 2012
- Prevention of CNS relapse in diffuse large B-cell lymphomaThe Lancet Oncology, 2011
- Immunologic and Virologic Predictors of AIDS-Related Non-Hodgkin Lymphoma in the Highly Active Antiretroviral Therapy EraJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphomaBlood, 2010
- The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphomaBlood, 2010
- Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients From AIDS Malignancies Consortium Clinical Trials 010 and 034Journal of Clinical Oncology, 2009
- Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer NetworkJournal of Clinical Oncology, 2008
- The Saw-Toothed Behavior of Power Versus Sample Size and Software SolutionsThe American Statistician, 2002
- The mdrl gene, responsible for multidrug-resistance, codes for P-glycoproteinBiochemical and Biophysical Research Communications, 1986
- Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphomaCancer, 1976